Caroline O’Connor becomes new CCO of rare disease healthtech Raremark® amid rapid growth

Raremark®, the healthtech company specializing in rare disease, has today named Caroline O’Connor as its new Chief Commercial Officer to drive the business forward.

Previously holding the position of Raremark’s SVP of Business Development, O’Connor will now take ownership of the company’s commercial focus and play a key role in growing its presence in the pharma industry.

O’Connor brings a passion for patient-centric healthcare, along with a wealth of experience in commercial roles in life sciences technology and services into her new position. Prior to joining Raremark, O’Connor’s focus was on eClinical technology, combined with establishing value and driving revenue growth from real-world evidence (RWE) and digital patient support programs in the post-approval setting.

“I’m excited to take the lead on the commercial strategy for the business. We’ve had some truly phenomenal growth, and it’s been a privilege to see it unfold and to work with the talented team who made it happen,” said O’Connor. “I can’t wait to keep the momentum going and help drive real change in rare disease research and patient lives.”

Jeremy Edwards, Raremark’s CEO, said: “I’m thrilled to name Caroline as our Chief Commercial Officer. Since joining the organization, her depth of industry knowledge and experience in motivating teams has made a significant impact. I’m confident she will lead us into the next exciting phase of our growth journey. This year we will reach even more patients, make an even bigger impact on their lives, and make further strides in rare disease research and development, and Caroline’s abilities will be instrumental in taking us there.”